PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23950549-0	2015	The effects of chronic candesartan treatment on cardiac and hepatic adenosine monophosphate-activated protein kinase in rats submitted to surgical stress.	candesartan	23-34	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	68-116	
23950549-2	2015	This study aimed to evaluate the effects of candesartan, an angiotensin II receptor blocker, on cardiac and hepatic AMPK activity basally as well as after surgical stress under general anesthesia.	candesartan	44-55	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	116-120	
23950549-5	2015	RESULTS: Chronic administration of candesartan increased hepatic AMPK activity approximately 4 times (p<0.05) while no significant change was demonstrated in cardiac AMPK.	candesartan	35-46	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	65-69	
23950549-7	2015	However, chronic treatment with candesartan decreased AMPK activity in both liver and heart after surgical stress under anesthesia (p<0.01 for both comparisons).	candesartan	32-43	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	54-58	
23950549-8	2015	CONCLUSIONS: While chronic candesartan treatment may stimulate AMPK activity in certain organs such as the liver, when combined with surgical stress under anesthesia it inhibits pathways regulating AMPK activity.	candesartan	27-38	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	63-67	
23950549-8	2015	CONCLUSIONS: While chronic candesartan treatment may stimulate AMPK activity in certain organs such as the liver, when combined with surgical stress under anesthesia it inhibits pathways regulating AMPK activity.	candesartan	27-38	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	198-202	
22217206-4	2012	This study was thus aimed to evaluate the effects of candesartan, an angiotensin II AT1 receptor blocker drug, on hypothalamic AMPK activity under basal conditions and after restraint in conscious rats or after surgical stress under general anesthesia.	candesartan	53-64	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	127-131	
22217206-7	2012	Chronic administration of candesartan significantly increased hypothalamic AMPK activity.	candesartan	26-37	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	75-79	
22217206-9	2012	The high levels of hypothalamic AMPK activation observed in candesartan-treated rats were not changed by restraint stress but were reduced to control levels by anesthesia and surgery.	candesartan	60-71	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	32-36	
22217206-10	2012	In conclusion, chronic candesartan treatment and restraint stress in conscious rats stimulate the hypothalamic AMPK activity, whereas surgical stress under anesthesia inhibits pathways regulating the AMPK activity even in candesartan-treated rats.	candesartan	23-34	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	111-115	
22217206-10	2012	In conclusion, chronic candesartan treatment and restraint stress in conscious rats stimulate the hypothalamic AMPK activity, whereas surgical stress under anesthesia inhibits pathways regulating the AMPK activity even in candesartan-treated rats.	candesartan	222-233	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	200-204